In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00.

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...

Volunteers packing meals at Monroe College. Hundreds of volunteers across Westchester County came together recently to honor the 23rd anniversary ...

Before Oct. 7, I hadn't wanted to play "T'filah," by Lera Auerbach. Now, I hope that it can bring us a little closer together ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

As part of its extensive offerings for the eczema community throughout October, NEA hosts The Ecz-hibition, a social ...

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...